Single-cell analysis of Crohn's disease reveals a detailed picture of inflammation in the gut

Researchers at the Broad Institute of MIT and Harvard and Massachusetts General Hospital have constructed a high-resolution cellular map of Crohn
Researchers at the Broad Institute of MIT and Harvard and Massachusetts General Hospital have constructed a high-resolution cellular map of Crohn's disease, a chronic condition in which a hyperactive immune system causes inflammation throughout the gut, leading to symptoms including abdominal pain, diarrhea, and weight loss. The disease is difficult to treat and often requires hospitalization.

Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy - ScienceDirect

Frontiers Single-Cell RNA Sequencing for Analyzing the Intestinal Tract in Healthy and Diseased Individuals

A detailed atlas of the developing brain

Ramnik Xavier named as a core member of Broad Institute

Multi-organ scRNA-seq reveals targeting pro- or anti-inflammatory regulators may be exploited for personalized treatment of immune diseases

Researchers map the immunology of the gut in children with IBD

Study identifies microbe-gut signalling as new treatment for IBD

Large sequencing effort links new genes to Crohn's disease risk

Ramnik Xavier named as a core member of Broad Institute

Single-Cell Sequencing of Developing Human Gut Reveals Transcriptional Links to Childhood Crohn's Disease - ScienceDirect

Stricturing Crohn's Disease Single-Cell RNA Sequencing Reveals Fibroblast Heterogeneity and Intercellular Interactions - ScienceDirect

Peter V. on LinkedIn: Grateful to do research in the fastest

Single-cell analysis of colonic epithelium reveals unexpected shifts in cellular composition and molecular phenotype in treatment-naïve adult Crohn's disease

PDF) P013 A single cell approach reveals immune cell dynamics in Inflammatory Bowel Disease (IBD) and highlights association of CD8 intraepithelial lymphocytes (IELs) with response to vedolizumab treatment